Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Natrogen Therapeutics International Inc.

Latest From Natrogen Therapeutics International Inc.

Emerging Markets Holding Up As Takeda Pursues Turnaround

Takeda continues to insist that its generics-hit business is being successfully turned around on the back of strong growth for new drugs in gastroenterology and oncology, as well as in emerging markets, which combined now account for around half of group revenues.

BioPharmaceutical China

Takeda Bigs Up Entyvio As Pillar Of GI Plans

Amid generic challenges to some of its older mainstay products in the field, Takeda is aiming to convince investors that its commitment to, and prospects in, the gastrointestinal (GI) space remain solid.

BioPharmaceutical Japan

Takeda Expects Entyvio To Become Its Flagship Drug With Blockbuster Sales

Christophe Weber, who will take over as CEO of Takeda on April 1, talked to “The Pink Sheet” about the company’s future, which will include a greater focus on gastroenterology fueled by the launch of Entyvio.

BioPharmaceutical Business Strategies

Deals Shaping The Medical Industry, January 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November through December 2013

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Natrogen Therapeutics International Inc.
  • Senior Management
  • Louis Wang, MD, Pres. & Chief Scientist
  • Contact Info
  • Natrogen Therapeutics International Inc.
    New York, NY